3-indol-3-yl-1-naphthalen-1-yl-propenone | 22883-34-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-indol-3-yl-1-naphthalen-1-yl-propenone
• 英文别名: 1--3--propenon-(1)；3-(1H-indol-3-yl)-1-naphthalen-1-ylprop-2-en-1-one
• CAS: 22883-34-7
• 化学式: C₂₁H₁₅NO
• 分子量: 297.356
• InChiKey: WFJBXBKHSXDGIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  32.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-氨基-2,6-二羟基嘧啶 、 3-indol-3-yl-1-naphthalen-1-yl-propenone 在 溶剂黄146 作用下， 反应 6.0h， 以75%的产率得到7‐(naphthalen‐1‐yl)pyrido[2,3‐d]pyrimidine‐2,4(1H,3H)‐dione
  参考文献：
  名称：

  First‐in‐class pyrido[2,3‐ d ]pyrimidine‐2,4(1 H ,3 H )‐diones against leishmaniasis and tuberculosis: Rationale, in vitro, ex vivo studies and mechanistic insights

  摘要：

  AbstractPyrido[2,3‐d]pyrimidine‐2,4(1H,3H)‐diones were synthesized, for the first time, from indole chalcones and 6‐aminouracil, and their ability to inhibit leishmaniasis and tuberculosis (Tb) infections was evaluated. The in vitro antileishmanial activity against promastigotes of Leishmania donovani revealed exceptional activities of compounds 3, 12 and 13, with IC50 values ranging from 10.23 ± 1.50 to 15.58 ± 1.67 µg/ml, which is better than the IC50 value of the standard drug pentostam of 500 μg/ml. The selectivity of the compounds towards Leishmania parasites was evaluated via ex vivo studies in Swiss albino mice. The efficiency of these compounds against Tb infection was then evaluated using the in vitro anti‐Tb microplate Alamar Blue assay. Five compounds, 3, 7, 8, 9 and 12, showed MIC100 values against the Mycobacterium tuberculosis H37Rv strain at 25 µg/ml, and compound 20 yielded an MIC100 value of 50 µg/ml. Molecular modelling of these compounds highlighted interactions with binding sites of dihydrofolate reductase, pteridine reductase and thymidylate kinase, thus establishing the rationale of their pharmacological activity against both pathogens, which is consistent with the in vitro results. From the above results, it is clear that compounds 3 and 12 are promising lead candidates for Leishmania and Mycobacterium infections and may be promising for coinfections.

  DOI：

  10.1002/ardp.202100440
• 作为产物：
  描述：

  1-萘乙酮 、 3-吲哚甲醛 在 哌啶 作用下， 以 乙醇 为溶剂， 生成 3-indol-3-yl-1-naphthalen-1-yl-propenone
  参考文献：
  名称：

  First‐in‐class pyrido[2,3‐ d ]pyrimidine‐2,4(1 H ,3 H )‐diones against leishmaniasis and tuberculosis: Rationale, in vitro, ex vivo studies and mechanistic insights

  摘要：

  AbstractPyrido[2,3‐d]pyrimidine‐2,4(1H,3H)‐diones were synthesized, for the first time, from indole chalcones and 6‐aminouracil, and their ability to inhibit leishmaniasis and tuberculosis (Tb) infections was evaluated. The in vitro antileishmanial activity against promastigotes of Leishmania donovani revealed exceptional activities of compounds 3, 12 and 13, with IC50 values ranging from 10.23 ± 1.50 to 15.58 ± 1.67 µg/ml, which is better than the IC50 value of the standard drug pentostam of 500 μg/ml. The selectivity of the compounds towards Leishmania parasites was evaluated via ex vivo studies in Swiss albino mice. The efficiency of these compounds against Tb infection was then evaluated using the in vitro anti‐Tb microplate Alamar Blue assay. Five compounds, 3, 7, 8, 9 and 12, showed MIC100 values against the Mycobacterium tuberculosis H37Rv strain at 25 µg/ml, and compound 20 yielded an MIC100 value of 50 µg/ml. Molecular modelling of these compounds highlighted interactions with binding sites of dihydrofolate reductase, pteridine reductase and thymidylate kinase, thus establishing the rationale of their pharmacological activity against both pathogens, which is consistent with the in vitro results. From the above results, it is clear that compounds 3 and 12 are promising lead candidates for Leishmania and Mycobacterium infections and may be promising for coinfections.

  DOI：

  10.1002/ardp.202100440

文献信息

• Regio- and diastereoselective construction of a new set of functionalized pyrrolidine, spiropyrrolidine and spiropyrrolizidine scaffolds appended with aryl- and heteroaryl moieties via the azomethine ylide cycloadditions
  作者：Vadla Rajkumar、Srinivasarao Arulananda Babu、Rayavarapu Padmavathi

  DOI：10.1016/j.tet.2016.07.053

  日期：2016.9

  Highly regio- and diastereoselective syntheses of a new set of functionalized pyrrolidines, spiro-pyrrolidine/pyrrolizidine oxindoles, spiroacenaphthylenolyl-pyrrolidines/pyrrolizidines and spiro-1,3-indandionolyl-pyrrolidines/pyrrolizidines appended with various aryl- and heteroaryl moieties via the azomethine ylide cycloaddition reaction are reported. The Ag-catalyzed [3+2] cycloaddition of azomethine

  一组新的功能化吡咯烷，螺并吡咯烷/吡咯并吡啶氧吲哚，螺并ac苯并菲咯啉基-吡咯烷/吡咯并吡啶和螺-1,3-吲哚并菲酰基-吡咯烷/吡咯并吡啶的高区域选择性和非对映选择性合成报道了环加成反应。Ag衍生自N的偶氮甲亚胺的[3 + 2]环加成反应用各种亚芳基/杂芳基亚甲基丙二酸-亚苄基亚氨基甘氨酸盐产生具有良好区域和非对映选择性的C-3，C-5-芳基/杂芳基取代的C-4，C-4-二氰基吡咯烷-2-羧酸酯支架。此外，研究了由不同的1,2-二羰基和α-氨基酸与基于吲哚/吡咯的偶极亲和剂的脱羧反应衍生的偶氮甲亚胺的[3 + 2]环加成反应。在丰富功能化的螺吡咯烷-和螺吡咯并吡啶骨架的文库的背景下，这些反应导致组装了各种螺并吡咯烷/吡咯并吡啶氧吲哚，螺并ena庚烯基-吡咯烷/吡咯并吡啶和螺-1,3-茚满二酮基-吡啶并吡啶在螺吡咯烷/吡咯烷环的C-3位的吲哚基和吡咯基部分。由甲亚胺叶立德环加成反应获得的图8
• First‐in‐class pyrido[2,3‐ <i>d</i> ]pyrimidine‐2,4(1 <i>H</i> ,3 <i>H</i> )‐diones against leishmaniasis and tuberculosis: Rationale, in vitro, ex vivo studies and mechanistic insights
  作者：Deepthi Ramesh、Deblina Sarkar、Annu Joji、Monica Singh、Amaresh K. Mohanty、Balaji G. Vijayakumar、Mitali Chatterjee、Dharmarajan Sriram、Suresh K. Muthuvel、Tharanikkarasu Kannan

  DOI：10.1002/ardp.202100440

  日期：2022.4

  AbstractPyrido[2,3‐d]pyrimidine‐2,4(1H,3H)‐diones were synthesized, for the first time, from indole chalcones and 6‐aminouracil, and their ability to inhibit leishmaniasis and tuberculosis (Tb) infections was evaluated. The in vitro antileishmanial activity against promastigotes of Leishmania donovani revealed exceptional activities of compounds 3, 12 and 13, with IC50 values ranging from 10.23 ± 1.50 to 15.58 ± 1.67 µg/ml, which is better than the IC50 value of the standard drug pentostam of 500 μg/ml. The selectivity of the compounds towards Leishmania parasites was evaluated via ex vivo studies in Swiss albino mice. The efficiency of these compounds against Tb infection was then evaluated using the in vitro anti‐Tb microplate Alamar Blue assay. Five compounds, 3, 7, 8, 9 and 12, showed MIC100 values against the Mycobacterium tuberculosis H37Rv strain at 25 µg/ml, and compound 20 yielded an MIC100 value of 50 µg/ml. Molecular modelling of these compounds highlighted interactions with binding sites of dihydrofolate reductase, pteridine reductase and thymidylate kinase, thus establishing the rationale of their pharmacological activity against both pathogens, which is consistent with the in vitro results. From the above results, it is clear that compounds 3 and 12 are promising lead candidates for Leishmania and Mycobacterium infections and may be promising for coinfections.